A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

Phase 1

• Conditions: Nonalcoholic Steatohepatitis (NASH)
• Interventions: Drug: XZP-5610 Tablet （for "Part C1"）; Drug: XZP-5610 Tablet (for Part B); Drug: XZP-5610 Tablet (for Part A); Drug: Placebo to match XZP-5610 Tablet (for Part B); Drug: Placebo to match XZP-5610 Tablet (for Part A); Drug: XZP-5610 Tablet for "Part C2"

• Registration Number: NCT04913090
• Lead Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.

Brief Summary

This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - multiple ascending dose (MAD) phase, and Part C - Food Effect (FE) phase.

Detailed Description

Part A and Part B studies were designed as single-center, randomized, double-blind, placebo-controlled, dose-escalation trials to assess the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single and multiple oral doses of XZP-5610 tablets in healthy adult subjects, and exploring preliminary food effects (non-high-fat meals) in the Part B study. Part C is a single-center, randomized, open, 2×2 crossover design designed to assess the foodeffects on PK of a single oral dose of XZP-5610 tablets in healthy adult subjects.

Study Timeline

• Study First Submitted: 2021-05-24
• Study Start: 2021-05-31
• Status Verified: 2021-06
• Study First Submitted QC: 2021-06-02
• Last Update Submitted: 2021-06-02
• Study First Posted: 2021-06-04
• Last Update Posted: 2021-06-04
• Primary Completion: 2022-03-04
• Study Completion: 2022-03-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

1. Healthy adult males or females aged 18 to 60 years (inclusive).
2. Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) in the range 19.0-28.0 kg/m2 for the non-obese group and in the range of 28.1 -35.0 kg/ 2 for the obese group (inclusive, BMI=weight/height2).
3. No plans to have children within the last 6 months, no plans to donate sperm/egg, and willing to use effective contraception within 6 months after the end of dosing
4. No clinically significant vital signs, physical examination, laboratory tests, or ECG or chest radiograph findings.
5. Subjects understand and comply with the study procedures, voluntarily participate, and sign an Informed Consent Form.

Read More

Exclusion Criteria

1. History or presence of severe systemic diseases such as endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic epilepsy) abnormalities.

2. History of clinically significant ECG abnormalities or family history of long QT syndrome (grandparents, parents and siblings)

   Part A:

   Any of the following was regarded as a criterion for exclusion:

   1. Confirmation of QTcF ≥ 450 ms by repeated measurements;
   2. Confirmation of QRS duration > 120 ms by repeated measurements;
   3. Confirmation of PR interval > 200 ms by repeated measurements;
   4. Findings that lead to difficulties in QTc measurement or difficult interpretation of QTc data;
   5. History of other risk factors for Torsades de Pointes tachycardia (e.g., heart failure, hypokalemia, family history of long QT syndrome);
   6. Presence of uncorrected hypokalemia or hypomagnesemia.

   Parts B and C:

   Any of the following was regarded as a criterion for exclusion:

   1. Family history of long QT syndrome (grandparents, parents and siblings);
   2. Resting QTcF ≥ 450 ms (males) or ≥ 460 ms (females) during the screening or baseline period.

3. Subjects with a known or suspected history of allergy to the test drug or its adjuvant components, or a history of clinically significant severe allergy (e.g., food, drug, latex allergy), or a history of atopic allergic disease (asthma, urticaria, eczematous dermatitis)

4. History of dysphagia or any gastrointestinal disorder affecting drug absorption at screening, including history of frequent nausea or vomiting of any etiology, history of irregular gastrointestinal motility such as habitual diarrhea, constipation or bowel pre-excitation syndrome, or history of major gastrointestinal surgery (e.g., gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastric division, or gastric banding)

5. History of pancreatic injury or pancreatitis at screening, or significantly elevated blood amylase (> 1.5 x ULN)

6. History of urinary tract obstruction or presence of urinary voiding difficulties at screening.

7. History of cancer (malignancy) at the time of screening.

8. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or syphilis antibody

9. History of significant drug abuse within 12 months prior to screening or positive urine drug screening

10. Regular alcohol consumption within 3 months prior to screening, consuming more than 3 alcoholic drinks per day (one drink is approximately equal to: beer 354 mL/12 ounces, wine 118 mL/4 ounces, or distilled spirits 29.5 mL/1 ounce), or evidence of alcohol abuse and excessive consumption as evidenced by alcohol breath test at screening (subjects who consume 4 alcoholic beverages per day may be enrolled at the investigator's (enrollment is at the discretion of the investigator).

11. History of smoking within 3 months prior to screening, or a positive urine nicotine test at screening, or who cannot give up smoking throughout the study period

12. Excessive daily intake of coffee, tea, cola, energy drinks, or other caffeinated beverages within 3 months prior to screening, with excess defined as more than 6 servings (one servingis approximately equal to 120 mg of caffeine).

13. Major surgery, or donation or loss of blood over 400 mL within 3 months prior to administration.

14. Participation in other clinical trials and treatment with investigational productinvestigational product within 3 months prior to administration.

15. Taken any prescription, over-the-counter, nutraceutical, herbal or proprietary Chinese medicine within 4 weeks prior to administration (or less than 5 half-lives of the drug from the start of the trial).

16. Women who are pregnant or breastfeeding, or of childbearing potential who are not using effective non-hormonal contraception (intrauterine device (IUD), barrier method with spermicide, or surgical sterilization, etc.) or are unwilling to continue using these methods during the trial until 6 months after discontinuation; men of childbearing potential who are unwilling to use physical methods of contraception during the trial until 6 months after discontinuation.

17. Systolic blood pressure ≥ 140 mmHg or < 90 mmHg, and/or diastolic blood pressure ≥ 90 mmHg or < 50 mmHg at screening or prior to dosing

18. Heart rate < 50 or > 100 beats/min at screening or prior to dosing.

19. The estimated glomerular filtration rate (eGFR) < 90 ml/min/ 1.73m2 at screening based on the Modification of Diet in Renal Disease Study (MDRD) formula (see Appendix 1 for calculation formula).

20. At screening, the liver function tests of non-obese group showed any measure of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or total bilirubin> upper limit of normal (ULN); the liver function tests of obese group showed AST, ALT, or ALP> 1.5 × ULN, or total bilirubin> ULN.

21. Fasting triglycerides > 200 mg/dL (2.27 mmol/L) at screening.

22. Fasting glucose > 5.6 mmol/L in the non-obese group and > 6.1 mmol/L or glycosylated hemoglobin (HbA1c) ≥ 6.5% in the obese group at screening.

23. Those who could not tolerate blood sample collection.

24. Subjects who are deemed by the investigator to be unsuitable for participation in the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Part C2-experimental	XZP-5610 Tablet （for "Part C1"）	Food Effect (FE) phase
Part B-experimental	XZP-5610 Tablet (for Part B)	multiple ascending dose (MAD) phase
Part A-experimental	XZP-5610 Tablet (for Part A)	Single Ascending Dose (SAD) phase
Part B-placebo	Placebo to match XZP-5610 Tablet (for Part B)	multiple ascending dose (MAD) phase
Part A-placebo	Placebo to match XZP-5610 Tablet (for Part A)	Single Ascending Dose (SAD) phase
Part C1-experimental	XZP-5610 Tablet for "Part C2"	Food Effect (FE) phase
Part C2-experimental	XZP-5610 Tablet for "Part C2"	Food Effect (FE) phase
Part C1-experimental	XZP-5610 Tablet （for "Part C1"）	Food Effect (FE) phase

Primary Outcome Measures

Name	Time	Method
AUClast	Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11
Subject incidence of adverse events for XZP-5610 versus placebo	From drug administration to study completion. Single dose：15 days , Multi dose: 42 days，Food Effect: 11 days
Tmax	Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11
AUCinf	Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11
CL/F	Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11
Cmax	Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11
T1/2	Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11
Vz/F	Single dose：Day1-Day4 , Multi dose: Day1,Day2,Day7,Day10,Day14-Day17，Food Effect:Day1-Day4,Day8-Day11

Trial Locations

Locations (1)

Peking University Third Hospital; 🇨🇳 Beijing, China